Hydrochlorothiazide

also known as HCTZ · HCT · Dichlozid · Diazide · Dichlozid Tab · H12.5 · HCT G.L · HTC · +3 more

Developed for: hypertensive disorder · essential hypertension · cardiovascular disorder · type 2 diabetes mellitus · chronic kidney disease · diabetes mellitus · congestive heart failure · heart failure
+34 more
· cerebrovascular disorder · diabetic kidney disease · heart disorder · metabolic syndrome X · nephrolithiasis · photosensitivity disease · stroke disorder · urolithiasis · abdominal obesity-metabolic syndrome · atherosclerosis · coronary microvascular disorder · Dent disease · early onset hypertension · glucose metabolism disease · hyperlipidemia, combined, 2 · hypertensive heart disease · impaired renal function disease · obstructive sleep apnea syndrome · peripheral arterial disease · prediabetes syndrome · preeclampsia · proteinuria · resistant hypertension · atrial fibrillation · autosomal dominant hypocalcemia · autosomal dominant polycystic kidney disease · endolymphatic hydrops · eustachian tube disorder · idiopathic hypercalciuria · intracerebral hemorrhage · nephrolithiasis, calcium oxalate · optic neuritis · secondary hyperparathyroidism of renal origin · vascular disorder
Investigated by: Novartis · Boehringer Ingelheim · Daiichi Sankyo · Organon and Co · Novartis Pharmaceuticals · Mylan Pharmaceuticals Inc
+176 more
· Sanofi · Boryung Pharmaceutical Co., Ltd · AstraZeneca · Damanhour University · GlaxoSmithKline · Imperial College London · UMC Utrecht · Bristol-Myers Squibb · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · Merck Sharp & Dohme LLC · Seoul National University Hospital · Takeda · Tehran University of Medical Sciences · Teva Pharmaceuticals USA · University of Birmingham · Yonsei University · Canadian Institutes of Health Research (CIHR) · IlDong Pharmaceutical Co Ltd · Imperial College Healthcare NHS Trust · Medical University of Vienna · Northern California Institute of Research and Education · Pfizer · Radboud University Medical Center · Royal College of Surgeons, Ireland · Sankyo Pharma Gmbh · Seoul National University Bundang Hospital · Shanghai Jiao Tong University School of Medicine · Sir Mortimer B. Davis - Jewish General Hospital · The University of Texas Health Science Center, Houston · University of California, San Diego · University of Cambridge · University of Florida · University of Kansas Medical Center · VA Office of Research and Development · Vanderbilt University · Wake Forest University Health Sciences · Abbott · Academic Medical Center - University of Amsterdam · Ajou University · Anna Posadzy-Małaczyńska · Aragon Health Research Institute (IISAragon) · Asan Medical Center · Assistance Publique - Hôpitaux de Paris · Association for the Promotion of Research in Atherosclerosis, Thrombosis and Vascular Biology · Azidus Brasil · Baker Heart and Diabetes Institute · Barts & The London NHS Trust · Biomedis International Ltd. · British Heart Foundation · CH Annecy Genevois · CH Issoire · CH Moulins-Yzeure · CH Puy en Velay · CH Riom · Cadila Pharnmaceuticals · Capital Medical University · Caribbean College of Family Physicians · Central Hospital, Nancy, France · Centro Neurológico de Pesquisa e Reabiitação, Brazil · Cheil General Hospital and Women's Healthcare Center · Chiang Mai University · Chonbuk National University Hospital · Chong-Jin Kim · Chonnam National University Hospital · Columbia University · Cornell University · Corporacion Parc Tauli · Creighton University · Daiichi Sankyo Korea Co., Ltd. · Danish Cardiovascular Research Academy · Danish Heart Foundation · Dialysis Clinic, Inc. · DongGuk University · Dr. Reddy's Laboratories Limited · all 182 on the full record

Regulatory milestones approvals, filings & regulatory actions · 3 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	CoAprovel	—	1998-10-14	europa.eu ↗
Label expansion	US (FDA)	HYDRODIURIL	—	1992-10-28	fda.gov ↗
Approved	US (FDA)	ESIDRIX	—	1959-02-12	fda.gov ↗

Trials 236 · started per year

today

US approved 1959

EU approved 1998

195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 04 trials
Phase 0	NCT04676399	Feb 2022 → Dec 2026 expected	chronic pain syndrome, hypertensive disorder	University of Kansas Medical Center	Active not recruiting	No outcome recorded
Phase 0	NCT03147092	Feb 2018 → Jun 2020	hypertensive disorder	Centro Neurológico de Pesquisa e Reabiitação, Brazil	Unknown	No outcome recorded
Phase 0	NCT02744456	Aug 2014 → Aug 2017	hypertensive disorder	Columbia University	Completed	No outcome recorded
Phase 0	NCT00649324	Oct 2005	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 132 trials · 2 met primary · 1 missed
Phase 1	NCT07544888	Nov 2025 → Mar 2026	heart disorder, hypertensive disorder	Shaikh Zayed Hospital, Lahore	Completed	No outcome recorded
Phase 1	NCT04934228	Jul 2021 → Aug 2026 overdue	diabetes mellitus, hypertensive disorder, obesity disorder	University of Kansas Medical Center	Recruiting	No outcome recorded
Phase 1	NCT04654312	Jan → Jul 2021	photosensitivity disease	Saarland University	Completed	No outcome recorded
Phase 1	NCT06083116	Aug → Oct 2019	type 2 diabetes mellitus	Jiangsu HengRui Medicine Co., Ltd.	Completed	No outcome recorded
Phase 1	NCT04197622	Mar 2019	—	Parc de Salut Mar	Completed	No outcome recorded
Phase 1	NCT03629067	Sep → Nov 2018	—	Boryung Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 1	NCT03387657	Jan → Mar 2018	type 2 diabetes mellitus	Sanofi	Completed	No outcome recorded
Phase 1	NCT03390465	Dec 2017 → Jan 2018	—	Boryung Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 1	NCT02183675	Jul → Oct 2014	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02094924	Apr → May 2014	hypertensive disorder	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT03889145	Dec 2013 → Feb 2014	—	IlDong Pharmaceutical Co Ltd	Completed	No outcome recorded
Phase 1	NCT01692717	Feb → May 2013	—	Azidus Brasil	Completed	No outcome recorded
Phase 1	NCT02962258	May → Jun 2011	—	Torrent Pharmaceuticals Limited	Completed	No outcome recorded
Phase 1	NCT01294631	Mar → Jul 2011	—	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Completed	No outcome recorded
Phase 1	NCT01198249	Sep 2010 → Feb 2011	essential hypertension	Yonsei University	Completed	No outcome recorded
Phase 1	NCT00871871	Mar 2009 → Feb 2010	hypertensive disorder	Merck Sharp & Dohme LLC	Completed	Missed primary
Phase 1	NCT02276378	Jul → Aug 2008	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00671424	Mar → May 2008	type 2 diabetes mellitus	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01019590	Nov 2006	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT01020214	Nov 2006	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT01149486	Jan → Feb 2004	—	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 1	NCT02262780	Dec 2003 → Feb 2004	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00835042	Oct → Nov 2003	—	Teva Pharmaceuticals USA	Completed	Met primary
Phase 1	NCT00834067	Oct → Nov 2003	—	Teva Pharmaceuticals USA	Completed	Met primary
Phase 1	NCT00648011	Aug 2003	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT00649441	Aug → Sep 2003	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT02262572	Apr → Aug 2003	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT00649233	Jan → Feb 2003	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT00649038	Dec 2002	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT00649597	Nov → Dec 2002	—	Mylan Pharmaceuticals Inc	Completed	No outcome recorded
Phase 1	NCT00223717	Jan 2001 → Jan 2017	hypertensive disorder	Vanderbilt University	Completed	No outcome recorded
Phase 1	NCT02176512	Sep → Oct 1998	—	Boehringer Ingelheim	Completed	No outcome recorded

Phase 213 trials · 1 met primary · 2 missed
Phase 2	NCT07634068	Jun 2026 → Jun 2027 expected	cerebrovascular disorder	Huashan Hospital	Not yet recruiting	No outcome recorded
Phase 2	NCT05897372	Aug 2023 → Sep 2024	diabetic kidney disease	Iain Bressendorff	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT03329599	Feb 2019 → Dec 2021	atherosclerosis	Northern California Institute of Research and Education	Completed	Missed primary
Phase 2	NCT03024476	Sep 2016 → Dec 2017	hypertensive disorder, ischemic stroke	Seoul National University Bundang Hospital	Completed	No outcome recorded
Phase 2	NCT02278471	Dec 2015 → Jun 2018	hyperlipidemia, hypertensive disorder	Vanderbilt University	Completed	Met primary
Phase 2	NCT02222480	Oct 2014 → May 2015	essential hypertension	Boryung Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 2	NCT01480791	Jan 2012 → Dec 2013	diabetes mellitus, hypertensive disorder	Sir Mortimer B. Davis - Jewish General Hospital	Withdrawn	No outcome recorded
Phase 2	NCT01302899	Jan → Dec 2011	—	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 2	NCT00567307	Jan → Dec 2009	cardiovascular disorder	Wake Forest University Health Sciences	Completed	Missed primary
Phase 2	NCT00388388	Mar 2007 → Dec 2009	hypertensive disorder, prediabetes syndrome	Sir Mortimer B. Davis - Jewish General Hospital	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00603590	Nov 2006 → Jun 2008	heart disorder, hyperlipidemia, hypertensive disorder	Tehran University of Medical Sciences	Completed	No outcome recorded
Phase 2	NCT00374855	Sep → Nov 2006	hypertensive disorder	Eli Lilly and Company	Completed	No outcome recorded
Phase 2	NCT00153049	Jun 2004 → Jun 2005	essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded

Phase 2/32 trials
Phase 2/3	NCT07469722	Mar 2026 → Jan 2028 expected	congestive heart failure	Hospital de Clinicas de Porto Alegre	Not yet recruiting	No outcome recorded
Phase 2/3	NCT00638482	Jul 2003 → Dec 2005	Dent disease, nephrolithiasis	Assistance Publique - Hôpitaux de Paris	Terminated	No outcome recorded
Phase 379 trials · 12 met primary · 6 missed
Phase 3	NCT05963568	Apr 2026 → Jan 2029 expected	stroke disorder	Northern California Institute of Research and Education	Recruiting	No outcome recorded
Phase 3	NCT07008365	Mar 2025 → Nov 2026 expected	cardio-renal syndrome, congestive heart failure	Aragon Health Research Institute (IISAragon)	Recruiting	No outcome recorded
Phase 3	NCT04465123	Aug 2020 → Jul 2022	acute kidney injury, heart failure	Chiang Mai University	Unknown	No outcome recorded
Phase 3	NCT03057431	Mar 2017 → Dec 2021	nephrolithiasis	Insel Gruppe AG, University Hospital Bern	Completed	Missed primary
Phase 3	NCT03246555	Jul 2016 → Aug 2019	—	Boryung Pharmaceutical Co., Ltd	Completed	Met primary
Phase 3	NCT03249285	Mar 2016 → Mar 2018	essential hypertension	Ospedale San Raffaele	Unknown	No outcome recorded
Phase 3	NCT03459560	Dec 2015 → Mar 2022	cardiovascular disorder	Tehran University of Medical Sciences	Unknown	Met primary
Phase 3	NCT02738632	May 2015 → Aug 2016	essential hypertension	IlDong Pharmaceutical Co Ltd	Completed	No outcome recorded
Phase 3	NCT02277691	Nov 2014 → Apr 2016	essential hypertension	Takeda	Completed	No outcome recorded
Phase 3	NCT01975246	Nov 2013 → Jun 2014	essential hypertension	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT01911780	Jul 2013 → Jan 2015	essential hypertension	Boehringer Ingelheim	Completed	Met primary
Phase 3	NCT02466490	Apr 2013 → Feb 2014	essential hypertension	Stendhal Americas, S.A.	Completed	No outcome recorded
Phase 3	NCT01313702	Oct 2012 → Apr 2014	cardiovascular disorder	Hospital do Coracao	Withdrawn	No outcome recorded
Phase 3	NCT01646437	Jun 2012 → Jun 2020	cardiovascular disorder	Population Health Research Institute	Completed	Mixed
Phase 3	NCT01245608	Oct 2011 → Jan 2018	cardiovascular disorder	Tehran University of Medical Sciences	Completed	Missed primary
Phase 3	NCT01307046	Mar 2011 → Feb 2012	essential hypertension	Organon and Co	Completed	Met primary
Phase 3	NCT01326676	Feb 2011 → Jul 2012	cardiovascular disorder	Imperial College London	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT01302691	Jan 2011 → Apr 2012	hypertensive disorder	Merck Sharp & Dohme LLC	Completed	Missed primary
Phase 3	NCT01259297	Jan 2011 → Nov 2012	—	Novartis Pharmaceuticals	Terminated	Missed primary
Phase 3	NCT01258673	Nov 2010 → Dec 2011	essential hypertension	Boryung Pharmaceutical Co., Ltd	Completed	No outcome recorded
Phase 3	NCT01057537	Jun 2010 → Jul 2012	cardiovascular disorder	Imperial College London	Completed	Met primary
Phase 3	NCT01113047	May → Oct 2010	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00923091	Jun 2009 → Jan 2011	essential hypertension	Daiichi Sankyo	Completed	Met primary
Phase 3	NCT00902538	Apr 2009 → Sep 2010	essential hypertension	Daiichi Sankyo	Completed	Mixed
Phase 3	NCT00818883	Feb → Nov 2009	essential hypertension	Takeda	Completed	Met primary
Phase 3	NCT00765674	Sep 2008 → Aug 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00667719	Jun 2008 → Oct 2009	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00705575	Jun 2008 → Apr 2009	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00548067	Sep 2007 → Mar 2008	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00441350	Jul 2007 → May 2008	hypertensive disorder	Menarini Group	Completed	Met primary
Phase 3	NCT00523744	Jul → Dec 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00447603	May → Oct 2007	hypertensive disorder	Organon and Co	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00459056	Apr 2007 → May 2010	abdominal obesity-metabolic syndrome, hypertensive disorder	St. Paul Heart Clinic	Completed	No outcome recorded
Phase 3	NCT00430508	Feb 2007 → Mar 2008	essential hypertension	Daiichi Sankyo	Completed	Met primary
Phase 3	NCT00430950	Feb 2007 → May 2008	essential hypertension	Daiichi Sankyo	Completed	Missed primary
Phase 3	NCT00434967	Jan 2007 → Jan 2008	hypertensive disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00402103	Nov 2006 → Apr 2008	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00387517	Oct 2006 → Aug 2007	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00386607	Oct 2006 → Jul 2008	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00386139	Sep 2006 → Jul 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00383929	Sep 2006 → Aug 2007	hypertensive disorder	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00872586	Aug 2006 → Jul 2007	essential hypertension	Daiichi Sankyo	Completed	No outcome recorded
Phase 3	NCT00355589	Jul 2006 → Mar 2007	essential hypertension	Pfizer	Completed	No outcome recorded
Phase 3	NCT00367094	Jul 2006 → ?	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00354991	Jun 2006 → Apr 2007	essential hypertension	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 3	NCT00338936	May 2006 → Sep 2007	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00326768	May 2006 → Aug 2007	essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00327587	May 2006 → Aug 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00449111	Mar → Sep 2006	hypertensive disorder	Organon and Co	Terminated	No outcome recorded
Phase 3	NCT00311740	Mar → Sep 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00289887	Feb 2006 → Feb 2007	hypertensive disorder	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00267943	Jan 2006 → Jan 2007	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00396656	Dec 2005 → Dec 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00257491	Nov 2005 → Aug 2006	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00273299	Nov 2005 → Jul 2006	hypertensive disorder	Novartis	Completed	Met primary
Phase 3	NCT00250562	Oct 2005 → Jun 2006	hypertensive disorder	Novartis	Completed	Met primary
Phase 3	NCT00239369	Oct 2005 → Aug 2006	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00400218	Sep 2005 → Jul 2006	essential hypertension	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00546052	Sep 2005 → Jan 2008	hypertensive disorder, metabolic disease	Organon and Co	Completed	Missed primary
Phase 3	NCT00139698	Sep 2005 → Jul 2006	essential hypertension	Pfizer	Completed	No outcome recorded
Phase 3	NCT00263003	Jun 2005 → ?	hypertensive disorder	Sanofi	Completed	No outcome recorded
Phase 3	NCT00146341	Apr 2005 → Sep 2006	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00398541	Mar 2005 → Apr 2007	hypertensive disorder	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00144222	Jan → Aug 2005	essential hypertension	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00307060	Dec 2004 → Jun 2005	hypertensive disorder	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00171015	Dec 2004 → Apr 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00095550	Oct 2004 → Jun 2005	hypertensive disorder	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00095394	Sep 2004 → May 2005	hypertensive disorder	Bristol-Myers Squibb	Completed	No outcome recorded
Phase 3	NCT00170989	Sep 2004 → Jul 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00241007	Dec 2003 → Mar 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00642096	Jun 2003 → Jul 2004	essential hypertension	AstraZeneca	Completed	No outcome recorded
Phase 3	NCT00092209	Apr → Nov 2002	essential hypertension	Organon and Co	Completed	No outcome recorded
Phase 3	NCT00185172	Jan 2002 → Jun 2005	essential hypertension	Sankyo Pharma Gmbh	Completed	No outcome recorded
Phase 3	NCT02177500	Jan → May 2000	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02177487	Jun 1999 → Jan 2000	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02177435	Feb → Sep 1999	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT02177422	Jun 1998 → Nov 1999	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 3	NCT00000525	Jul 1986 → Sep 1989	cardiac arrest, hypertensive disorder, sudden arrhythmia death syndrome	University of California, San Francisco	Completed	No outcome recorded
Phase 3	NCT02493322	? → Jun 2025	essential hypertension	EMS	Withdrawn	No outcome recorded

Phase 484 trials · 11 met primary · 6 missed
Phase 4	NCT07593612	Jun 2026 → Jan 2027 expected	heart failure	Lucrecia Maria Burgos	Not yet recruiting	No outcome recorded
Phase 4	NCT05917275	Apr 2024 → Oct 2025	essential hypertension	Radboud University Medical Center	Unknown	No outcome recorded
Phase 4	NCT05443932	Mar → Dec 2024	urolithiasis	Medical University of Vienna	Unknown	No outcome recorded
Phase 4	NCT05171686	Feb 2023 → Oct 2025	chronic kidney disease, hypertensive disorder	VA Office of Research and Development	Completed	No outcome recorded
Phase 4	NCT05049616	Oct 2021 → Jun 2022	preeclampsia	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 4	NCT03423355	Sep 2021 → Mar 2023	type 2 diabetes mellitus	University Hospital Tuebingen	Withdrawn	No outcome recorded
Phase 4	NCT04192110	Aug 2020	chronic kidney disease	VA Office of Research and Development	Withdrawn	No outcome recorded
Phase 4	NCT04330300	Apr 2020 → Jul 2021	COVID-19, essential hypertension	National University of Ireland, Galway, Ireland	Suspended	No outcome recorded Stop: Business
Phase 4	NCT04242758	Jun → Dec 2019	glucose metabolism disease, impaired renal function disease	University of Pisa	Unknown	No outcome recorded
Phase 4	NCT03978884	Jun 2019 → May 2020	diabetes mellitus, hypertensive disorder	The University of The West Indies	Withdrawn	No outcome recorded
Phase 4	NCT03892148	May 2019 → Jan 2023	heart failure	University Hospital, Clermont-Ferrand	Completed	No outcome recorded
Phase 4	NCT03682692	Jun 2018 → Jun 2021	hypertensive disorder	Shanghai Jiao Tong University School of Medicine	Completed	Missed primary
Phase 4	NCT03461003	Apr 2018 → Nov 2020	early onset hypertension	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 4	NCT03254849	Dec 2017 → Apr 2020	type 2 diabetes mellitus	Profil Institute for Metabolic Research GmbH	Completed	No outcome recorded
Phase 4	NCT02742467	Jun 2017 → Jun 2018	hypertensive disorder	University of Abuja	Completed	Met primary
Phase 4	NCT02646397	Feb 2016 → Dec 2017	chronic kidney disease	Shanghai Changzheng Hospital	Unknown	No outcome recorded
Phase 4	NCT02377661	Mar 2015 → May 2017	hypertensive disorder	Wilhelminenspital Vienna	Completed	Met primary
Phase 4	NCT02699125	Jan 2015 → Jun 2016	obstructive sleep apnea syndrome	University of California, San Diego	Completed	No outcome recorded
Phase 4	NCT02710071	Jan 2015 → Apr 2016	essential hypertension	University of California, San Diego	Completed	No outcome recorded
Phase 4	NCT02294539	Aug 2014 → May 2016	hypertensive disorder	Chong-Jin Kim	Completed	Met primary
Phase 4	NCT02217852	Aug 2014 → Jan 2016	hypertensive disorder	West China Hospital	Unknown	No outcome recorded
Phase 4	NCT02100462	Mar 2014 → Dec 2016	hypertensive disorder	Creighton University	Unknown	No outcome recorded
Phase 4	NCT01977430	Nov 2013 → Mar 2015	chronic kidney disease	Corporacion Parc Tauli	Unknown	No outcome recorded
Phase 4	NCT01198496	Oct 2010 → Dec 2017	essential hypertension, stroke disorder	Biomedis International Ltd.	Unknown	Missed primary
Phase 4	NCT01138423	Aug 2010 → Feb 2012	hypertensive disorder, metabolic syndrome X	UMC Utrecht	Completed	No outcome recorded
Phase 4	NCT01056731	Feb 2010 → Oct 2011	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT01070030	Jan → Oct 2010	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00994617	Jan 2010 → Dec 2014	essential hypertension, resistant hypertension	University of Cambridge	Unknown	Mixed
Phase 4	NCT02351973	Nov 2009 → Jul 2015	essential hypertension	University of Cambridge	Unknown	No outcome recorded
Phase 4	NCT01012479	Oct 2009 → May 2010	essential hypertension	Takeda	Completed	No outcome recorded
Phase 4	NCT00896389	Oct 2009 → Dec 2012	hypertensive disorder	University of Maryland, Baltimore	Completed	Missed primary
Phase 4	NCT00931710	Jul 2009 → Jan 2010	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00902304	Jul 2009 → Jul 2011	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00926289	Jun 2009 → Apr 2010	hypertensive disorder	Boehringer Ingelheim	Completed	Met primary
Phase 4	NCT00942994	Jun 2009 → Mar 2010	hypertensive disorder	Novartis	Completed	Met primary
Phase 4	NCT01819220	Apr 2009 → Nov 2014	hypertensive disorder	Yonsei University	Completed	No outcome recorded
Phase 4	NCT00787605	Nov 2008 → Jan 2010	diabetes mellitus, hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00795847	Nov 2008 → Nov 2010	hypertensive disorder	Kurume University	Completed	No outcome recorded
Phase 4	NCT00791258	Nov 2008 → Aug 2009	hypertensive disorder	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT00797316	Nov 2008 → Dec 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00765947	Sep 2008 → Aug 2009	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT00772577	Aug 2008 → Mar 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00739596	Jul 2008 → Mar 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00654745	May 2008 → Apr 2009	essential hypertension, type 2 diabetes mellitus	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT00698646	Apr 2008 → Jun 2009	essential hypertension	Novartis Pharmaceuticals	Completed	Missed primary
Phase 4	NCT00670566	Apr 2008 → Mar 2009	hypertensive disorder	Sanofi	Completed	No outcome recorded
Phase 4	NCT00687206	Mar → May 2008	erectile dysfunction, hypertensive disorder	Federico II University	Completed	No outcome recorded
Phase 4	NCT00496834	Feb 2008 → Sep 2009	hypertensive disorder	Organon and Co	Completed	Missed primary
Phase 4	NCT00621153	Feb 2008 → Mar 2009	hypertensive disorder	AstraZeneca	Completed	Met primary
Phase 4	NCT00492128	Sep 2007 → May 2009	hypertensive disorder	Yokohama City University Medical Center	Completed	No outcome recorded
Phase 4	NCT01431508	Aug 2007 → Jun 2009	essential hypertension	Organon and Co	Completed	No outcome recorded
Phase 4	NCT00457483	Aug 2007 → Dec 2010	essential hypertension	Radboud University Medical Center	Completed	No outcome recorded
Phase 4	NCT00425997	Dec 2006 → Oct 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00412932	Dec 2006 → Apr 2008	hypertensive disorder	Daiichi Sankyo	Completed	Met primary
Phase 4	NCT00430638	Dec 2006 → Oct 2007	hypertensive disorder	Daiichi Sankyo	Completed	Met primary
Phase 4	NCT00439738	Dec 2006 → Nov 2007	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01425411	Nov 2006 → Nov 2008	hypertensive disorder, hypertensive heart disease	Mustafa Kemal University	Completed	No outcome recorded
Phase 4	NCT00426478	Nov 2006 → Sep 2007	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT00403481	Nov 2006 → Nov 2007	hypertensive disorder	Daiichi Sankyo	Completed	Met primary
Phase 4	NCT00443612	Sep 2006 → Oct 2008	hypertensive disorder	Sanofi	Completed	No outcome recorded
Phase 4	NCT00400777	Aug 2006 → Nov 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00890591	Aug 2006 → Jun 2007	essential hypertension	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT00607035	May 2006 → Apr 2008	hypertensive disorder	Jichi Medical University	Completed	No outcome recorded
Phase 4	NCT00311155	Mar 2006 → Apr 2008	essential hypertension	Sankyo Pharma Gmbh	Completed	No outcome recorded
Phase 4	NCT00335673	Feb → Nov 2006	hypertensive disorder	Sanofi	Completed	No outcome recorded
Phase 4	NCT00280540	Dec 2005 → Aug 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00246519	Oct 2005 → Dec 2010	hypertensive disorder	University of Florida	Completed	No outcome recorded
Phase 4	NCT00535925	Oct 2005 → Dec 2011	diabetic kidney disease	University of Campania Luigi Vanvitelli	Completed	No outcome recorded
Phase 4	NCT00185120	Sep 2005 → Sep 2006	hypertensive disorder	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT00168779	Sep 2005 → Jul 2006	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00821574	Jul 2005 → Mar 2007	hyperlipidemia, combined, 2	Novartis	Completed	No outcome recorded
Phase 4	NCT00157963	Feb 2005 → Feb 2006	essential hypertension	Organon and Co	Completed	No outcome recorded
Phase 4	NCT00170937	Nov 2004 → Mar 2006	hypertensive disorder, metabolic syndrome X	Novartis	Completed	Missed primary
Phase 4	NCT00185068	Mar → Oct 2004	hypertensive disorder	Daiichi Sankyo	Completed	No outcome recorded
Phase 4	NCT00171782	Feb → Dec 2004	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00154271	Jan 2004 → Jun 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00847834	Dec 2003 → Jun 2004	essential hypertension	Sanofi	Completed	No outcome recorded
Phase 4	NCT00240448	Sep 2003 → Jun 2004	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00171054	Sep 2003 → Oct 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00171561	Mar 2003 → Sep 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00306696	Oct 2002 → Jan 2004	diabetes mellitus	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT03921736	Jan 2000 → Mar 2001	essential hypertension	Anna Posadzy-Małaczyńska	Completed	No outcome recorded
Phase 4	NCT02172586	Jan 2000 → Jan 2002	hypertensive disorder	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT00133692	Sep 1997 → Feb 2003	coronary artery disorder, hypertensive disorder	University of Florida	Completed	Met primary

Phase not applicable22 trials · 1 missed
—	NCT06790927	Feb 2025 → Dec 2026 expected	hypertensive disorder	Shanghai Jiao Tong University School of Medicine	Not yet recruiting	No outcome recorded
—	NCT07020104	Jan 2025 → Dec 2039 expected	chronic kidney disease	Academic Medical Center - University of Amsterdam	Recruiting	No outcome recorded
—	NCT06491940	Aug 2024 → Jul 2025 overdue	proteinuria	RESnTEC, Institute of Research	Not yet recruiting	No outcome recorded
—	NCT06710600	Sep 2022 → Apr 2024	photosensitivity disease	Medical University of Vienna	Completed	No outcome recorded
—	NCT04182854	Oct 2019 → Feb 2020	antidepressant type abuse	Capital Medical University	Unknown	No outcome recorded
—	NCT02765009	Jun 2016 → Jul 2019	—	Central Hospital, Nancy, France	Completed	Missed primary
—	NCT02255253	Oct 2014 → Feb 2015	hypertensive disorder	The George Institute for Global Health, China	Completed	No outcome recorded
—	NCT02711670	Feb 2014 → Jun 2017	urolithiasis	VA New York Harbor Healthcare System	Completed	No outcome recorded
—	NCT04371874	Jan 2014 → Jul 2017	hypertensive disorder	First Affiliated Hospital Xi'an Jiaotong University	Completed	No outcome recorded
—	NCT01858610	Mar → Apr 2013	—	Damanhour University	Completed	No outcome recorded
—	NCT01858623	Feb → Mar 2013	—	Damanhour University	Completed	No outcome recorded
—	NCT01767259	Oct → Dec 2012	—	Damanhour University	Completed	No outcome recorded
—	NCT01658657	Oct 2012 → Jul 2014	hypertensive disorder, proteolytic capacity of plasma	University of North Carolina, Chapel Hill	Completed	No outcome recorded
—	NCT01767298	Oct → Dec 2012	—	Damanhour University	Completed	No outcome recorded
—	NCT01506505	Jul 2012 → Jul 2013	cerebrovascular disorder, peripheral arterial disease	UMC Utrecht	Completed	Mixed
—	NCT00822107	Jan 2009 → Jan 2013	Gitelman syndrome	Oregon Health and Science University	Completed	No outcome recorded
—	NCT00700583	May → Jun 2008	—	Seoul National University Hospital	Completed	No outcome recorded
—	NCT00424801	Jan 2007 → Dec 2008	coronary microvascular disorder, essential hypertension	University of Aarhus	Terminated	No outcome recorded
—	NCT00834600	Dec 2005 → Oct 2011	hypertensive disorder	The Louis & Rachel Rudin Foundation	Completed	No outcome recorded
—	NCT00690521	Oct 2004 → Nov 2009	congestive heart failure	University of New Mexico	Completed	No outcome recorded
—	NCT00162474	Sep 2003 → Dec 2030 expected	—	Hadassah Medical Organization	Recruiting	No outcome recorded
—	NCT00247910	Oct 2001 → Jun 2006	hypertensive disorder	University of British Columbia	Completed	No outcome recorded

Comparator or background therapy167 trials
Phase 0	NCT04423627 Comparator	Jun 2021 → Jul 2025	hypertensive disorder	University of Iowa	Completed	No outcome recorded
Phase 0	NCT01804777 Comparator	Mar 2013 → Dec 2014	hypertensive disorder, proteinuria, type 2 diabetes mellitus	University of New Mexico	Terminated	No outcome recorded
Phase 0	NCT00574834 Comparator	Mar 2007 → Aug 2014	metabolic syndrome X	University of Maryland, Baltimore	Terminated	No outcome recorded Stop: Business
Phase 1	NCT06205407 Comparator	Dec 2023 → Mar 2024	—	Pfizer	Completed	No outcome recorded
Phase 1	NCT03971929 Comparator	Jul 2019 → Sep 2020	hypertensive disorder	Jiangsu HengRui Medicine Co., Ltd.	Completed	No outcome recorded
Show all 167 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 12

Date	Issuer	Release
2019-05-31	Hanmi Pharmaceutical Company Limited	Results <보도자료> 발매 10주년 맞은 아모잘탄, 국제학술지 10번째 등재 hanmi.co.kr ↗ 특히, 투여 20주 후의 24시간 실시간 중심ㆍ활동혈압 변화는 아모잘탄 투여군(각각 -9.4, -10.1mmHg)이 ARB/HCTZ 투여군(각각 -6.3, -6.7mmHg)보다 통계적으로 우월한 것으로 나타났다.
2018-06-12	Hanmi Pharmaceutical Company Limited	Results <보도자료> 한미약품, 아모잘탄·로벨리토 임상 결과 유럽고혈압학회 발표 hanmi.co.kr ↗ 연구결과, 아모잘탄 투여군에서 ARB/hydrochlorothiazide 복합제 투여군 대비, 24시간 활동혈압 중 수축기 혈압의 조절 효과가 우수하게 나타났으며, 야간의 수축기 중심혈압과 맥파전달속도(PWV, Pulse Wave Velocity), 평탄지수(SI, Smoothness Index)와 같은 혈역학적 지수에 있어 우수한 조절 효과를 보였다.
2016-11-07	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Approval of Generic Tribenzor® in the United States tevapharm.com ↗ Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced approval of generic Tribenzor®1(olmesartan medoxomil, amlodipine and hydrochlorothiazide) tablets in the U.S. and is in the final stages of launch preparation.
2012-04-02	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Launch of Generic Avapro® and Generic Avalide® in the United States; Awarded 180-Day Period of Marketing Exclusivity tevapharm.com ↗ As the first company to file Abbreviated New Drug Applications (ANDA) containing paragraph IV certifications for both of these products, Teva has been awarded a 180-day period of marketing exclusivity.
2010-12-21	Daiichi Sankyo	Regulatory Daiichi Sankyo Announces First European Approval for Sevikar HCT(R), a New Three-in-one Combination Product for the Treatment of High Blood Pressure* daiichisankyo.com ↗ Daiichi Sankyo Europe announced today that Sevikar HCT® is now approved in Germany, the first market to launch this new once-daily three-in-one combination product for the treatment of high blood pressure (BP).
2010-07-27	Daiichi Sankyo	Regulatory FDA APPROVES TRIBENZOR™, A NEW THREE-IN-ONE COMBINATION PRODUCT FOR THE TREATMENT OF HIGH BLOOD PRESSURE daiichisankyo.com ↗ FDA APPROVES TRIBENZOR™, A NEW THREE-IN-ONE COMBINATION PRODUCT FOR THE TREATMENT OF HIGH BLOOD PRESSURE
2010-04-07	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Final Approval of Generic Hyzaar® and Cozaar® tevapharm.com ↗ Jerusalem, April 7, 2010 - Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's generic versions of Merck's antihypertensive agents Hyzaar® (hydrochlorothiazide; losartan potassium) and Cozaar® (losartan potassium).
2007-03-11	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Receives First U.S. Approval For Generic UNIRETIC® Tablets tevapharm.com ↗ Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA)announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDAfor Moexipril HCland HydrochlorothiazideTablets, 7.5 mg/12.5 mg, 15 mg/12.5 mg and 15 mg/25 mg.
2006-06-14	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Tentative Approval of Losartan Potassium & Hydrochlorothiazide Tablets tevapharm.com ↗ Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application ("ANDA") for Losartan Potassium and Hydrochlorothiazide Tablets, 50 mg/12.5 mg and 100 mg/25 mg.
2005-10-07	Daiichi Sankyo	Regulatory European Mutual Certification Completed for Antihypertensive daiichisankyo.com ↗ has successfully cleared the screening by relevant European member countries and is scheduled to obtain marketing authorization for the European market
2002-07-01	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Approval of Lisinopril Tablets and Lisinopril HCTZ Tablets tevapharm.com ↗ has issued final approval for the company's ANDA for Lisinopril Tablets USP, 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg and 40 mg as well as its ANDA for Lisinopril and Hydrochlorothiazide Tablets
2001-09-19	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Approval of Enalapril / HCTZ Tablets tevapharm.com ↗ Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U. S. Food and Drug Administration (FDA) has issued final approval for the company's ANDA for ENALAPRIL MALEATE / HYDROCHLOROTHIAZIDE TABLETS.

All press releases naming this drug 12 releases

Date	Issuer	Release
2019-05-31	Hanmi Pharmaceutical Company Limited	<보도자료> 발매 10주년 맞은 아모잘탄, 국제학술지 10번째 등재 hanmi.co.kr ↗
2018-06-12	Hanmi Pharmaceutical Company Limited	<보도자료> 한미약품, 아모잘탄·로벨리토 임상 결과 유럽고혈압학회 발표 hanmi.co.kr ↗
2016-11-07	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Approval of Generic Tribenzor® in the United States tevapharm.com ↗
2012-04-02	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Launch of Generic Avapro® and Generic Avalide® in the United States; Awarded 180-Day Period of Marketing Exclusivity tevapharm.com ↗
2010-12-21	Daiichi Sankyo	Daiichi Sankyo Announces First European Approval for Sevikar HCT(R), a New Three-in-one Combination Product for the Treatment of High Blood Pressure* daiichisankyo.com ↗
2010-07-27	Daiichi Sankyo	FDA APPROVES TRIBENZOR™, A NEW THREE-IN-ONE COMBINATION PRODUCT FOR THE TREATMENT OF HIGH BLOOD PRESSURE daiichisankyo.com ↗
2010-04-07	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Final Approval of Generic Hyzaar® and Cozaar® tevapharm.com ↗
2007-03-11	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Receives First U.S. Approval For Generic UNIRETIC® Tablets tevapharm.com ↗
2006-06-14	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Tentative Approval of Losartan Potassium & Hydrochlorothiazide Tablets tevapharm.com ↗
2005-10-07	Daiichi Sankyo	European Mutual Certification Completed for Antihypertensive daiichisankyo.com ↗
2002-07-01	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Approval of Lisinopril Tablets and Lisinopril HCTZ Tablets tevapharm.com ↗
2001-09-19	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Approval of Enalapril / HCTZ Tablets tevapharm.com ↗

Evidence & citations 14 cited values

Every value below carries the sentence it was read from. 431 sources stand behind the page.

Field	Value	Cited text
Known as	hydrochlorothiazide	“The participant's blood pressure medication regimen will then be altered to initiate a thiazide-type (hydrochlorothiazide or chlorthalidone) or loop diuretic (furosemide,...” NCT04192110 ↗ 382 “OBJECTIVE: To compare the antihypertensive efficacy and safety of once-daily triple therapy with amlodipine (Aml) 10 mg, valsartan (Val) 320 mg, and hydrochlorothiazide (HCTZ)...” PMID 23721363 ↗ Jul 2013 “The purpose of this trial is to evaluate the safety and efficacy of combination therapy of aliskiren/hydrochlorothiazide (HCTZ) 150/25 mg and 300/25 mg compared with HCTZ 25 mg...” NCT00387517 ↗ “Antihypertensive Effects of a Fixed-dose Combination of Losartan and Hydrochlorothiazide Plus Amlodipine Versus a Hydrochlorothiazide and Atenolol Combination Plus Amlodipine...” NCT00140959 ↗ “A Study on the Efficacy and Safety of Olmesartan Medoxomil and Its Combination With Hydrochlorothiazide Compared With an ACE Inhibitor and Its Combination With a Calcium...” NCT00185120 ↗ “Then, losartan 50 mg for 4 weeks, then titrate to losartan 100 mg at Week 4, then titrate to losartan 100 mg + hydrochlorothiazide (HCTZ) 12.5 mg at Week 8, and finally titrate...” NCT00289887 ↗ “Participants will be randomized to one of three first-line antihypertensive agents: (1) the ACE inhibitor perindopril, (2) the AT1 receptor antagonist losartan, or (3) the...” PMID 32039215 ↗ Jan 2020 “COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With...” NCT00449111 ↗ “Successful treatment of hypertension accounts for improvements in markers of diastolic function - a pilot study comparing hydrochlorothiazide-based and amlodipine-based...” PMID 19960134 ↗ Dec 2009 “In intervention clusters, lay CHWs independently prescribed and titrated a fixed-dose combination of amlodipine and hydrochlorothiazide, guided by a mobile clinical decision...” PMID 41680483 ↗ Feb 2026 “Two randomized studies were designed to assess the safety, tolerability and efficacy of losartan 100 mg (L100) plus hydrochlorothiazide 12.5 mg (H12.5) in a single fixed-dose...” PMID 24990091 ↗ Jul 2014 Show 372 more sources
Known as	Diazide	“Diazide” NCT00621153 ↗
Known as	Dichlozid	“Dichlozid 1 Tab.(Hydrochlorothiazide 25.0 mg) would be administered orally once” NCT02739672 ↗ 1 “Dichlozid 1 Tab.(Hydrochlorothiazide 12.5 mg) would be administered orally once” NCT03032315 ↗
Known as	Dichlozid Tab	“Dichlozid Tab® (hydrochlorothiazide 25 mg)” NCT00496834 ↗
Known as	H12.5	“50 mg losartan potassium (L50), 12.5 mg hydrochlorothiazide (H12.5), and 5 mg amlodipine besylate (A5)” NCT01302691 ↗
Known as	HCT	“The majority of patients with essential hypertension of moderate severity (WHO grade 2) require combination therapy. We aimed to investigate whether the single-pill combination...” PMID 21117946 ↗ Nov 2010 6 “Angiotensin-converting enzyme inhibitors combined with higher doses of hydrochlorothiazide (HCT), that is, 25 mg daily, have been recognized as an effective form of...” PMID 18463672 ↗ May 2008 “PURPOSE: To investigate the pharmacokinetic/pharmacodynamic (PK/PD) interaction between irbesartan (IRB) and hydrochlorothiazide (HCT) in normotensive subjects.” PMID 25545238 ↗ Feb 2015 “At visit 4, if the patients did not achieve BP goal, HCT 12.5 mg/day was added to Aliskiren/Amlodipine/HCT (300/10/12.5 mg/day) for 4 weeks.” NCT01070030 ↗ “single-pill combination of the direct renin inhibitor aliskiren and hydrochlorothiazide (HCT)” PMID 19203020 ↗ Dec 2008 “Hydrochlorothiazide (HCT)” NCT00775814 ↗ “Hydrochlorothiazide (HCT)” NCT07593612 ↗
Known as	HCT G.L	“hydrochlorothiazide (HCT G.L) 25mg” NCT06710600 ↗
Known as	HCTZ	“The general aim and clinical objective of this trial is to determine the effect of telmisartan 80 mg compared to losartan 50 mg + HCTZ (Hydrochlorothiazide) 12.5 mg on...” NCT02183701 ↗ 108 “OBJECTIVE: The aim of this study was to determine whether a triple combination of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) had a...” PMID 20678674 ↗ Jul 2010 “The purpose of this trial is to evaluate the safety and efficacy of combination therapy of aliskiren/hydrochlorothiazide (HCTZ) 150/25 mg and 300/25 mg compared with HCTZ 25 mg...” NCT00387517 ↗ “The authors examined effects of valsartan and hydrochlorothiazide (HCTZ) combined and alone on insulin sensitivity (using homeostasis model assessment-insulin resistance...” PMID 19120715 ↗ Dec 2008 “In patients with acute heart failure, the addition of hydrochlorothiazide (HCTZ) to furosemide increased the diuretic response in the CLOROTIC trial (Combining Loop with...” PMID 40590131 ↗ Jul 2025 “Then, losartan 50 mg for 4 weeks, then titrate to losartan 100 mg at Week 4, then titrate to losartan 100 mg + hydrochlorothiazide (HCTZ) 12.5 mg at Week 8, and finally titrate...” NCT00289887 ↗ “This 28- to 54-week, open-label, multicenter study evaluated the safety and efficacy of a triple combination, aliskiren with amlodipine and hydrochlorothiazide (HCTZ), in...” PMID 23205748 ↗ Aug 2012 “Olmesartan medoxomil was uptitrated to 40 mg/day (weeks 4-6), then olmesartan medoxomil/hydrochlorothiazide (HCTZ) 40/12.5 mg per day (weeks 7-9), and olmesartan medoxomil/HCTZ...” PMID 20653330 ↗ 2010 “The impact of an ARB, with or without hydrochlorothiazide (HCTZ), on glycaemic factors and the risk for developing diabetes in hypertensive patients with the metabolic syndrome...” PMID 20147971 ↗ Feb 2010 “An eight week study to compare the effect of a fixed dose combination of Telmisartan 40 mg plus hydrochlorothiazide (HCTZ) 12.5 mg to Telmisartan 40 mg alone on diastolic and...” NCT02177500 ↗ “Hydrochlorothiazide (HCTZ) ATC class: C03AA03 Form: Tablet Dose range: Phase 1: 25mg (2 x 12.5mg tablet) Phase 2: 50mg (4 x 12.5mg tablet) Maximum allowed dose: 50mg...” NCT02351973 ↗ Show 98 more sources
Known as	HTC	“administration of hydrochlorothiazide (HTC) once daily for 4 days (10 patients)” NCT01276288 ↗
Known as	Hydrochlorothiazid	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01879527 ↗
Known as	hydrochlorothiazide 25 milligrams	“hydrochlorothiazide 25 milligrams” NCT07008365 ↗
Known as	Hydrochlorthiazide	“Hydrochlorthiazide® (Hydrochlorothiazide)” NCT02774460 ↗
Action	Inhibit	“Na-Cl co-transporter activity is inhibited by thiazides.” PMID 20555294 ↗ Aug 2010
Route	Oral	“Tablets, Oral” NCT00095394 ↗